PS

Prajesh Shantilal Mehta

Active Director Director DIN 08212703
DIN 08212703 First appointment Mar 2019 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2019
Shareholding value β€’β€’β€’β€’ Premium profile

About Prajesh Shantilal Mehta

Data last updated:

Prajesh Shantilal Mehta is a Director at Hasta Phrmaceutical Private Limited (since 2019). The company operates in Pharma.

DIN 08212703
Primary Designation Director
Industry Pharma
First Appointment 19 Mar 2019
Oldest Company Age 30 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Hasta Phrmaceutical Private Limited U24110MH1996PTC098258
Director19 Mar 20191996Under Process Of Striking Off

Board colleagues of Prajesh Shantilal Mehta

NameDINCompanyDesignation
Ankit Ashok Jain00350348Hasta Phrmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Hasta Phrmaceutical Private Limited
Premium access

Shareholding and investment profile for Prajesh Shantilal Mehta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Prajesh Shantilal Mehta

Prajesh Shantilal Mehta currently holds 1 directorship: Hasta Phrmaceutical Private Limited (Director, since 19 Mar 2019).

Prajesh Shantilal Mehta was first appointed on 19 Mar 2019 as Director at Hasta Phrmaceutical Private Limited.

The current boards of Prajesh Shantilal Mehta's companies include Ankit Ashok Jain (Hasta Phrmaceutical Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available